首页 > 最新文献

Revista espanola de cardiologia最新文献

英文 中文
Consecuencias clínicas de los límites superiores de referencia ajustados al sexo de la troponina cardiaca I ultrasensible en el diagnóstico del infarto agudo de miocardio 诊断急性心肌梗死中超敏性心肌钙素I的性别调整参考阈值的临床影响
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-23 DOI: 10.1016/j.recesp.2025.05.001
María Rubini Giménez , Luca Koechlin , Pedro López-Ayala , Carlos Spagnuolo , Jasper Boeddinghaus , Karin Wildi , Thomas Nestelberger , Hanna Tkachenko , Daniel Basic , Emel Kaplan , Jude Formambuh , Paolo Bima , Jonas Glaeser , Luca Crisanti , Óscar Miró , F. Javier Martín-Sánchez , Michael Christ , Dagmar I. Keller , Danielle M. Gualandro , Damian Kawecki , Arnold von Eckardstein

Introduction and objectives

It is unclear whether applying sex-specific rather than uniform upper reference limits (URLs) for high-sensitivity cardiac troponin I (hs-cTnI) improves diagnostic equity between women and men with suspected myocardial infarction (MI). We compared the diagnostic performance of these 2 approaches.

Methods

In an international, prospective, multicenter study of patients presenting with suspected MI, the final diagnosis was centrally adjudicated twice by 2 independent cardiologists using all available information, including serial measurements of hs-cTnI-Architect, once using the uniform URL (26.2 ng/L) and once using sex-specific URLs (women: 15.6 ng/L; men: 34.2 ng/L). The primary outcome was the diagnostic performance of uniform vs sex-specific URLs at presentation for MI.

Results

Among 7137 eligible patients, 2434 were women (34%), median age 65 years, and 4703 were men (66%), median age 59 years. Using the uniform URL, 348 women and 880 men were adjudicated as having MI. At presentation, the sensitivity and specificity of hs-cTnI were high and similar in women (77%; 95%CI, 72-81, and 93%; 95%CI, 92-94, respectively) and men (79%; 95%CI, 77-82, and 94%; 95%CI, 93-94). Using sex-specific URLs, the sensitivity and specificity were 85% (95%CI, 81-89) and 91% (95%CI, 89-92) in women vs 74% (95%CI, 71-77), and 95% (95%CI, 94-95) in men (P < .001). Using sex-specific URLs, diagnostic reclassification occurred in 27 patients, 12 women (upgrade to MI) and 15 men (downgrade from MI), representing 0.4%, (95%CI, 0.3-0.6) of all patients.

Conclusions

Using a uniform URL for hs-cTnI provides high and similar diagnostic sensitivity and specificity in women and men. Contrary to expectations, sex-specific URLs introduced sex-related disparities. These findings support the use of a uniform rather than sex-specific URL in the diagnosis of MI.
目前尚不清楚应用性别特异性而非统一的高敏感性心肌肌钙蛋白I (hs-cTnI)上限参考限值(url)是否能提高疑似心肌梗死(MI)患者男女之间的诊断公平性。我们比较了这两种方法的诊断性能。方法在一项国际、前瞻性、多中心的研究中,两名独立的心脏病专家使用所有可用信息(包括hs-cTnI-Architect的系列测量)对疑似心肌梗死患者的最终诊断进行了两次集中裁决,一次使用统一的URL (26.2 ng/L),一次使用性别特异性URL(女性:15.6 ng/L;男性:34.2 ng/L)。结果在7137例符合条件的患者中,2434例为女性(34%),中位年龄65岁,4703例为男性(66%),中位年龄59岁。使用统一的URL, 348名女性和880名男性被判定为MI。目前,hs-cTnI的敏感性和特异性在女性(77%;95%CI, 72-81和93%;95%CI, 92-94)和男性(79%;95%CI, 77-82和94%;95%CI, 93-94)中很高且相似。使用性别特异性url,女性的敏感性和特异性分别为85% (95% ci, 81-89)和91% (95% ci, 89-92),男性为74% (95% ci, 71-77)和95% (95% ci, 94-95) (P < 0.001)。使用性别特异性url, 27例患者发生诊断重新分类,12例女性(升级为心肌梗死)和15例男性(降级为心肌梗死),占所有患者的0.4% (95%CI, 0.3-0.6)。结论使用统一的URL对hs-cTnI具有较高的诊断敏感性和特异性,且在男性和女性中具有相似的诊断敏感性和特异性。与预期相反,特定性别的url引入了与性别相关的差异。这些发现支持在心肌梗死诊断中使用统一的URL而不是性别特异性URL。
{"title":"Consecuencias clínicas de los límites superiores de referencia ajustados al sexo de la troponina cardiaca I ultrasensible en el diagnóstico del infarto agudo de miocardio","authors":"María Rubini Giménez ,&nbsp;Luca Koechlin ,&nbsp;Pedro López-Ayala ,&nbsp;Carlos Spagnuolo ,&nbsp;Jasper Boeddinghaus ,&nbsp;Karin Wildi ,&nbsp;Thomas Nestelberger ,&nbsp;Hanna Tkachenko ,&nbsp;Daniel Basic ,&nbsp;Emel Kaplan ,&nbsp;Jude Formambuh ,&nbsp;Paolo Bima ,&nbsp;Jonas Glaeser ,&nbsp;Luca Crisanti ,&nbsp;Óscar Miró ,&nbsp;F. Javier Martín-Sánchez ,&nbsp;Michael Christ ,&nbsp;Dagmar I. Keller ,&nbsp;Danielle M. Gualandro ,&nbsp;Damian Kawecki ,&nbsp;Arnold von Eckardstein","doi":"10.1016/j.recesp.2025.05.001","DOIUrl":"10.1016/j.recesp.2025.05.001","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>It is unclear whether applying sex-specific rather than uniform upper reference limits (URLs) for high-sensitivity cardiac troponin I (hs-cTnI) improves diagnostic equity between women and men with suspected myocardial infarction (MI). We compared the diagnostic performance of these 2 approaches.</div></div><div><h3>Methods</h3><div>In an international, prospective, multicenter study of patients presenting with suspected MI, the final diagnosis was centrally adjudicated twice by 2 independent cardiologists using all available information, including serial measurements of hs-cTnI-Architect, once using the uniform URL (26.2 ng/L) and once using sex-specific URLs (women: 15.6 ng/L; men: 34.2 ng/L). The primary outcome was the diagnostic performance of uniform vs sex-specific URLs at presentation for MI.</div></div><div><h3>Results</h3><div>Among 7137 eligible patients, 2434 were women (34%), median age 65 years, and 4703 were men (66%), median age 59 years. Using the uniform URL, 348 women and 880 men were adjudicated as having MI. At presentation, the sensitivity and specificity of hs-cTnI were high and similar in women (77%; 95%CI, 72-81, and 93%; 95%CI, 92-94, respectively) and men (79%; 95%CI, 77-82, and 94%; 95%CI, 93-94). Using sex-specific URLs, the sensitivity and specificity were 85% (95%CI, 81-89) and 91% (95%CI, 89-92) in women vs 74% (95%CI, 71-77), and 95% (95%CI, 94-95) in men (<em>P</em> <!-->&lt;<!--> <!-->.001). Using sex-specific URLs, diagnostic reclassification occurred in 27 patients, 12 women (upgrade to MI) and 15 men (downgrade from MI), representing 0.4%, (95%CI, 0.3-0.6) of all patients.</div></div><div><h3>Conclusions</h3><div>Using a uniform URL for hs-cTnI provides high and similar diagnostic sensitivity and specificity in women and men. Contrary to expectations, sex-specific URLs introduced sex-related disparities. These findings support the use of a uniform rather than sex-specific URL in the diagnosis of MI.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 12","pages":"Pages 1064-1075"},"PeriodicalIF":5.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Registro español de marcapasos. XXII informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2024) 西班牙心脏起搏器登记。西班牙心脏学会心脏节律协会第二十二次正式报告(2024年)
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-23 DOI: 10.1016/j.recesp.2025.07.006
Francisco Javier García-Fernández , Rocío Cózar-León , Josep Navarro-Manchón , Manuel Molina-Lerma , David Calvo , en representación de los colaboradores del Registro español de marcapasos

Introduction

This report presents data on cardiac pacing system implants in Spain during 2024.

Methods

The registry is based on data voluntarily submitted by implanting centers to the Heart Rhythm Association of the Spanish Society of Cardiology via the national online platform, CardioDispositivos. Additional data sources included: a) data provided by device manufacturers and distributors, b) the European pacemaker patient card, and c) local databases submitted by implanting centers.

Results

A total of 128 hospitals submitted data to the registry (16 more than in 2023 and 46 more than in 2022). In total, 26 412 units were reported (an 8.5% increase compared with 2023 and 60.8% compared with 2022), vs 47 162 units reported by Eucomed (European Confederation of Medical Suppliers Associations). Among these, 1715 were cardiac resynchronization pacemakers. Leadless pacemaker use continued to rise (1049 devices), accounting for 2.2% of all pacemakers. The most common indication was atrioventricular block, followed by atrial tachyarrhythmia with slow ventricular response. Devices included in remote monitoring also increased: the most notable growth was observed in high-energy resynchronization devices (87%) and leadless pacemakers (38%). Moderate increases were also noted for conventional cardiac resynchronization pacemakers (59%) and standard pacemakers (39%).

Conclusions

Participation in the pacemaker registry continues to grow, reaching 56% of the number of units reported by manufacturers to Eucomed. Remote monitoring maintains the slow but steady growth trend observed in recent years.
Full English text available from:www.revespcardiol.org/en
本报告介绍了2024年西班牙心脏起搏系统植入的数据。方法该注册表基于植入中心通过国家在线平台CardioDispositivos自愿向西班牙心脏病学会心律协会提交的数据。其他数据来源包括:a)设备制造商和经销商提供的数据,b)欧洲起搏器患者卡,以及c)植入中心提交的本地数据库。结果共有128家医院向注册中心提交数据,比2023年增加16家,比2022年增加46家。总共报告了26412个单位(与2023年相比增长8.5%,与2022年相比增长60.8%),而Eucomed(欧洲医疗供应商协会联合会)报告了47162个单位。其中1715例为心脏再同步起搏器。无铅起搏器的使用持续上升(1049台),占所有起搏器的2.2%。最常见的适应症是房室传导阻滞,其次是房性心动过速伴心室反应缓慢。远程监控设备也有所增加:最显著的增长是高能再同步设备(87%)和无铅起搏器(38%)。常规心脏再同步起搏器(59%)和标准起搏器(39%)也有中度增加。参与起搏器注册的人数持续增长,达到制造商向Eucomed报告的单位数量的56%。远程监测维持了近年来观察到的缓慢但稳定的增长趋势。完整的英文文本可从:www.revespcardiol.org/en
{"title":"Registro español de marcapasos. XXII informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2024)","authors":"Francisco Javier García-Fernández ,&nbsp;Rocío Cózar-León ,&nbsp;Josep Navarro-Manchón ,&nbsp;Manuel Molina-Lerma ,&nbsp;David Calvo ,&nbsp;en representación de los colaboradores del Registro español de marcapasos","doi":"10.1016/j.recesp.2025.07.006","DOIUrl":"10.1016/j.recesp.2025.07.006","url":null,"abstract":"<div><h3>Introduction</h3><div>This report presents data on cardiac pacing system implants in Spain during 2024.</div></div><div><h3>Methods</h3><div>The registry is based on data voluntarily submitted by implanting centers to the Heart Rhythm Association of the Spanish Society of Cardiology via the national online platform, <em>CardioDispositivos</em>. Additional data sources included: <em>a)</em> data provided by device manufacturers and distributors, <em>b)</em> the European pacemaker patient card, and <em>c)</em> local databases submitted by implanting centers.</div></div><div><h3>Results</h3><div>A total of 128 hospitals submitted data to the registry (16 more than in 2023 and 46 more than in 2022). In total, 26 412 units were reported (an 8.5% increase compared with 2023 and 60.8% compared with 2022), vs 47 162 units reported by Eucomed (European Confederation of Medical Suppliers Associations). Among these, 1715 were cardiac resynchronization pacemakers. Leadless pacemaker use continued to rise (1049 devices), accounting for 2.2% of all pacemakers. The most common indication was atrioventricular block, followed by atrial tachyarrhythmia with slow ventricular response. Devices included in remote monitoring also increased: the most notable growth was observed in high-energy resynchronization devices (87%) and leadless pacemakers (38%). Moderate increases were also noted for conventional cardiac resynchronization pacemakers (59%) and standard pacemakers (39%).</div></div><div><h3>Conclusions</h3><div>Participation in the pacemaker registry continues to grow, reaching 56% of the number of units reported by manufacturers to Eucomed. Remote monitoring maintains the slow but steady growth trend observed in recent years.</div><div><em>Full English text available from</em>:<span><span>www.revespcardiol.org/en</span><svg><path></path></svg></span></div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 12","pages":"Pages 1076-1087"},"PeriodicalIF":5.9,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevención primaria en personas mayores: diferencias por sexo en la persistencia al tratamiento con estatinas y el control del colesterol 老年人的初级预防:坚持使用他汀类药物治疗和胆固醇控制方面的性别差异
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-22 DOI: 10.1016/j.recesp.2025.05.007
Sara Malo , María José Rabanaque , Adriana Gamba , José Manuel Vinuesa-Hernando , Aida Moreno-Juste , María Jesús Lallana , Jesús Cebollada , Isabel Aguilar-Palacio

Introduction and objectives

This study aimed to analyze sex differences in statin persistence and associated factors among individuals aged 70 years and older in Spain who initiated statin therapy for primary prevention of cardiovascular disease. Additionally, it assessed the role of sex in low-density lipoprotein cholesterol (LDL-C) control based on the intensity of statin therapy used.

Methods

This was an observational longitudinal study conducted within the CARhES (Cardiovascular risk factors for health services research) cohort. Individuals aged ≥ 70 years who initiated statin therapy for primary prevention of cardiovascular disease between 2018 and 2020 were included. Two-year statin persistence was assessed by sex. Considering major cardiovascular events and death as competing risks, the risk of statin discontinuation and its associated factors were estimated using cumulative incidence functions and Fine and Gray analysis. The proportion of men and women achieving LDL-C target levels was also calculated.

Results

A total of 4936 older adults (61.7% women) were included. Compared with men, women had higher mean LDL-C levels prior to statin initiation, a greater pharmacological burden, were less likely to receive high-intensity statins, and demonstrated lower persistence. No variables were statistically associated with discontinuation among women. In men, the adjusted HR for discontinuation was 1.03 (95%CI: 1.00-1.06) per 10 mg/dL increase in baseline LDL-C level. Among persistent statin users, women were less likely than men to achieve LDL-C targets, particularly when treated with low- to moderate-intensity statins.

Conclusions

Significant sex differences exist in statin persistence, associated factors, and achievement of LDL-C targets among older adults. These findings highlight the importance of considering sex-specific factors when evaluating the appropriateness of statin use in this population.
本研究旨在分析西班牙70岁及以上开始他汀类药物治疗以预防心血管疾病的个体中他汀类药物持久性及相关因素的性别差异。此外,它评估了性别在低密度脂蛋白胆固醇(LDL-C)控制中的作用,基于所使用的他汀类药物治疗的强度。方法:这是一项在CARhES(心血管危险因素卫生服务研究)队列中进行的观察性纵向研究。纳入了年龄≥70岁、在2018年至2020年期间开始他汀类药物治疗用于心血管疾病一级预防的个体。2年的他汀类药物使用情况按性别进行评估。考虑到主要心血管事件和死亡是相互竞争的风险,使用累积发生率函数和Fine and Gray分析来估计他汀类药物停药的风险及其相关因素。还计算了达到LDL-C目标水平的男性和女性的比例。结果共纳入4936名老年人,其中女性占61.7%。与男性相比,女性在他汀类药物治疗前的平均LDL-C水平较高,这是一个更大的药理学负担,接受高强度他汀类药物治疗的可能性较小,并且表现出较低的持久性。没有统计学变量与女性停药相关。在男性中,基线LDL-C水平每增加10 mg/dL,停药后的调整HR为1.03 (95%CI: 1.00-1.06)。在持续使用他汀类药物的患者中,女性达到LDL-C目标的可能性低于男性,特别是在使用低至中等强度的他汀类药物治疗时。结论:在老年人中,他汀类药物的持久性、相关因素和LDL-C目标的实现存在显著的性别差异。这些发现强调了在评估该人群中他汀类药物使用的适宜性时考虑性别特异性因素的重要性。
{"title":"Prevención primaria en personas mayores: diferencias por sexo en la persistencia al tratamiento con estatinas y el control del colesterol","authors":"Sara Malo ,&nbsp;María José Rabanaque ,&nbsp;Adriana Gamba ,&nbsp;José Manuel Vinuesa-Hernando ,&nbsp;Aida Moreno-Juste ,&nbsp;María Jesús Lallana ,&nbsp;Jesús Cebollada ,&nbsp;Isabel Aguilar-Palacio","doi":"10.1016/j.recesp.2025.05.007","DOIUrl":"10.1016/j.recesp.2025.05.007","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This study aimed to analyze sex differences in statin persistence and associated factors among individuals aged 70 years and older in Spain who initiated statin therapy for primary prevention of cardiovascular disease. Additionally, it assessed the role of sex in low-density lipoprotein cholesterol (LDL-C) control based on the intensity of statin therapy used.</div></div><div><h3>Methods</h3><div>This was an observational longitudinal study conducted within the CARhES (Cardiovascular risk factors for health services research) cohort. Individuals aged ≥ 70 years who initiated statin therapy for primary prevention of cardiovascular disease between 2018 and 2020 were included. Two-year statin persistence was assessed by sex. Considering major cardiovascular events and death as competing risks, the risk of statin discontinuation and its associated factors were estimated using cumulative incidence functions and Fine and Gray analysis. The proportion of men and women achieving LDL-C target levels was also calculated.</div></div><div><h3>Results</h3><div>A total of 4936 older adults (61.7% women) were included. Compared with men, women had higher mean LDL-C levels prior to statin initiation, a greater pharmacological burden, were less likely to receive high-intensity statins, and demonstrated lower persistence. No variables were statistically associated with discontinuation among women. In men, the adjusted HR for discontinuation was 1.03 (95%CI: 1.00-1.06) per 10<!--> <!-->mg/dL increase in baseline LDL-C level. Among persistent statin users, women were less likely than men to achieve LDL-C targets, particularly when treated with low- to moderate-intensity statins.</div></div><div><h3>Conclusions</h3><div>Significant sex differences exist in statin persistence, associated factors, and achievement of LDL-C targets among older adults. These findings highlight the importance of considering sex-specific factors when evaluating the appropriateness of statin use in this population.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 15-23"},"PeriodicalIF":5.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluación mediante ecocardiografía tridimensional de la geometría del anillo tricuspídeo en niños con cardiopatías congénitas 利用三维超声心动图评估患有先天性心脏病的儿童的三尖环几何形状
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-19 DOI: 10.1016/j.recesp.2025.05.013
Ramona Ghenghea , Clement Karsenty , Pierrick Pyra , Aitor Guitarte , Yves Dulac , Paul Vignaud , Philippe Acar , Khaled Hadeed

Introduction and objectives

The tricuspid annulus (TA) in congenital heart diseases (CHD) may undergo significant changes in size, shape, and function due to hemodynamic overload. This study aimed to compare TA remodeling in children with CHD based on the type of right ventricle (RV) overload, using three-dimensional transthoracic echocardiography (3D-TTE).

Methods

This prospective case-control study included children with CHD who were divided into 2 groups based on the type of RV overload. Using 3D-TTE, we assessed the dimensions of the right chambers, the surface area, and the tenting volume of the TA, and analyzed the correlation among these measurements.

Results

A total of 90 patients were enrolled: 30 with pretricuspid overload (atrial septal defect and partial anomalous pulmonary venous connection), 33 with posttricuspid overload (pulmonary regurgitation after RV outflow tract surgery), and 27 healthy controls. 3D TA surface area was larger in the pretricuspid group than in the posttricuspid group (median 6.60 cm2/m2 vs 5.16 cm2/m2; P = .01) and was correlated with right atrial (RA) volume (P = .0001, r = 0.66) and RA surface area (P < .0001, r = 0.74) in the pretricuspid group. The tenting volume was greater in the posttricuspid group than in the control group. The 3D TA surface area and tenting volume were not correlated with RV end-diastolic volume.

Conclusions

3D modeling of the TA using 3D-TTE is feasible and provides insights into TA remodeling in different RV overload conditions. RA volume and surface area are key determinants of TA size, which could have an impact on therapeutic strategies in patients with tricuspid regurgitation.
前言和目的先天性心脏病(CHD)患者的三尖瓣环(TA)可能由于血流动力学超载而在大小、形状和功能上发生显著变化。本研究旨在利用三维经胸超声心动图(3D-TTE)比较基于右心室(RV)过载类型的冠心病儿童TA重塑。方法本前瞻性病例对照研究纳入冠心病患儿,根据右心室负荷类型分为两组。使用3D-TTE,我们评估了右心室的尺寸、表面积和TA的帐篷体积,并分析了这些测量结果之间的相关性。结果共纳入90例患者:30例为三尖瓣前负荷过重(房间隔缺损和部分肺静脉连接异常),33例为三尖瓣后负荷过重(右心室流出道手术后肺返流),27例为健康对照。三尖瓣前组三维TA表面积大于三尖瓣后组(中位数6.60 cm2/m2 vs 5.16 cm2/m2, P = 0.01),且与三尖瓣前组右心房(RA)容积(P = 0.0001, r = 0.66)和RA表面积(P < 0.0001, r = 0.74)相关。三尖瓣后组的帐篷体积大于对照组。三维TA表面积和支帐篷容积与右心室舒张末期容积无相关性。结论利用3D-TTE技术对TA进行三维建模是可行的,为研究不同RV过载条件下TA的重构提供了新的思路。RA体积和表面积是TA大小的关键决定因素,这可能对三尖瓣反流患者的治疗策略产生影响。
{"title":"Evaluación mediante ecocardiografía tridimensional de la geometría del anillo tricuspídeo en niños con cardiopatías congénitas","authors":"Ramona Ghenghea ,&nbsp;Clement Karsenty ,&nbsp;Pierrick Pyra ,&nbsp;Aitor Guitarte ,&nbsp;Yves Dulac ,&nbsp;Paul Vignaud ,&nbsp;Philippe Acar ,&nbsp;Khaled Hadeed","doi":"10.1016/j.recesp.2025.05.013","DOIUrl":"10.1016/j.recesp.2025.05.013","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The tricuspid annulus (TA) in congenital heart diseases (CHD) may undergo significant changes in size, shape, and function due to hemodynamic overload. This study aimed to compare TA remodeling in children with CHD based on the type of right ventricle (RV) overload, using three-dimensional transthoracic echocardiography (3D-TTE).</div></div><div><h3>Methods</h3><div>This prospective case-control study included children with CHD who were divided into 2 groups based on the type of RV overload. Using 3D-TTE, we assessed the dimensions of the right chambers, the surface area, and the tenting volume of the TA, and analyzed the correlation among these measurements.</div></div><div><h3>Results</h3><div>A total of 90 patients were enrolled: 30 with pretricuspid overload (atrial septal defect and partial anomalous pulmonary venous connection), 33 with posttricuspid overload (pulmonary regurgitation after RV outflow tract surgery), and 27 healthy controls. 3D TA surface area was larger in the pretricuspid group than in the posttricuspid group (median 6.60<!--> <!-->cm<sup>2</sup>/m<sup>2</sup> vs 5.16<!--> <!-->cm<sup>2</sup>/m<sup>2</sup>; <em>P</em> <!-->=<!--> <!-->.01) and was correlated with right atrial (RA) volume (<em>P</em> <!-->=<!--> <!-->.0001, r<!--> <!-->=<!--> <!-->0.66) and RA surface area (<em>P</em> <!-->&lt;<!--> <!-->.0001, r<!--> <!-->=<!--> <!-->0.74) in the pretricuspid group. The tenting volume was greater in the posttricuspid group than in the control group. The 3D TA surface area and tenting volume were not correlated with RV end-diastolic volume.</div></div><div><h3>Conclusions</h3><div>3D modeling of the TA using 3D-TTE is feasible and provides insights into TA remodeling in different RV overload conditions. RA volume and surface area are key determinants of TA size, which could have an impact on therapeutic strategies in patients with tricuspid regurgitation.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 59-67"},"PeriodicalIF":5.9,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precisión diagnóstica del cociente cuantitativo de flujo en lesiones intermedias no culpables de pacientes con infarto agudo de miocardio con elevación del segmento ST ST段升高急性心肌梗死患者非罪过性中间损伤定量流量系数的诊断准确性
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-10 DOI: 10.1016/j.recesp.2025.05.010
Emilio Alfonso Rodríguez , Josep Gómez-Lara , Ramón López-Palop , Enrique Gutiérrez , Luis Renier Goncalves Ramírez , José Valencia , Alfonso Jurado-Román , Juan Gabriel Córdoba Soriano , Antonio Gómez-Menchero , Estefanía Fernández-Peregrina , Carlos Cortés , Paula Tejedor , Raúl Millán , Guillermo Sánchez-Elvira , Tamara García-Camarero , José Antonio Linares Vicente , Eva Rúmiz , Rosa María Cardenal Piris , Irene Elizondo Rua , Jean Paul Vílchez , Joan Antoni Gómez-Hospital

Introduction and objectives

The reliability of quantitative flow ratio (QFR) has been questioned. Our aim was to evaluate the diagnostic accuracy of QFR in intermediate nonculprit lesions during the index ST-segment elevation myocardial infarction (STEMI) procedure compared with positive pressure wire-based fractional flow reserve (FFR ≤ 0.80) in a staged procedure.

Methods

This was a substudy of the multicenter, controlled, and randomized VULNERABLE trial, including 428 intermediate nonculprit lesions from 388 consecutive STEMI patients undergoing FFR assessment in a staged procedure between 1 and 60 days. Off-line QFR analyses were performed during both the index and staged procedures. The primary objective was to assess the diagnostic accuracy of index QFR compared with staged positive FFR.

Results

Angiographic vessel diameter (2.80 ± 0.59 vs 2.91 ± 0.57 mm; P < .01), stenosis severity (51.33 ± 8.04% vs 50.54 ± 7.63%; P = .053), and QFR values (0.85 ± 0.09 vs 0.86 ± 0.09; P = .120) showed minimal changes between the index and staged procedures. Moderate concordance was observed between index QFR and staged FFR (kappa index = 0.629; intraclass correlation coefficient = 0.641). The diagnostic accuracy of index QFR for predicting positive FFR was good (area under the curve = 0.825). An index QFR cutoff ≤ 0.80 showed moderate sensitivity (72%) and excellent specificity (91%). An index QFR ≤ 0.87 achieved a sensitivity of 86% for detecting lesions with positive FFR, with 55% of lesions presenting QFR ≤ 0.87 at the index procedure.

Conclusions

Index QFR demonstrated good diagnostic accuracy for identifying lesions with positive FFR in a staged procedure. However, an index QFR cutoff value of ≤ 0.80 showed moderate sensitivity and may underdiagnose approximately 3 out of 10 lesions with positive FFR. An index QFR ≤ 0.87 provided higher sensitivity and may help avoid invasive (staged) procedures in many patients.
定量流量比(QFR)的可靠性一直受到质疑。我们的目的是评估QFR在st段抬高型心肌梗死(STEMI)过程中对中间非罪魁祸首病变的诊断准确性,并与分期手术中基于正压丝的分数血流储备(FFR≤0.80)进行比较。这是多中心、对照和随机的VULNERABLE试验的一项亚研究,包括388例连续STEMI患者的428个中间非罪魁祸首病变,在1至60天的分期过程中进行FFR评估。离线QFR分析在索引和分级过程中进行。主要目的是评估QFR指数与分期阳性FFR的诊断准确性。结果血管造影血管直径(2.80±0.59 vs 2.91±0.57 mm, P < 01)、狭窄严重程度(51.33±8.04% vs 50.54±7.63%,P = 0.053)和QFR值(0.85±0.09 vs 0.86±0.09,P = 0.120)在指数和分期手术之间变化最小。指标QFR与分期FFR有中等程度的一致性(kappa指数= 0.629,类内相关系数= 0.641)。指标QFR预测FFR阳性的诊断准确率较好(曲线下面积= 0.825)。QFR指数截止值≤0.80,灵敏度中等(72%),特异度极佳(91%)。指数QFR≤0.87对于检测FFR阳性病变的灵敏度为86%,其中55%的病变在指数程序中QFR≤0.87。结论指数QFR在分期诊断FFR阳性病变方面具有良好的准确性。然而,指数QFR截断值≤0.80表示中度敏感性,并且可能在FFR阳性的10个病变中有3个未被诊断。QFR指数≤0.87提供了更高的敏感性,并可能有助于避免许多患者的侵入性(分期)手术。
{"title":"Precisión diagnóstica del cociente cuantitativo de flujo en lesiones intermedias no culpables de pacientes con infarto agudo de miocardio con elevación del segmento ST","authors":"Emilio Alfonso Rodríguez ,&nbsp;Josep Gómez-Lara ,&nbsp;Ramón López-Palop ,&nbsp;Enrique Gutiérrez ,&nbsp;Luis Renier Goncalves Ramírez ,&nbsp;José Valencia ,&nbsp;Alfonso Jurado-Román ,&nbsp;Juan Gabriel Córdoba Soriano ,&nbsp;Antonio Gómez-Menchero ,&nbsp;Estefanía Fernández-Peregrina ,&nbsp;Carlos Cortés ,&nbsp;Paula Tejedor ,&nbsp;Raúl Millán ,&nbsp;Guillermo Sánchez-Elvira ,&nbsp;Tamara García-Camarero ,&nbsp;José Antonio Linares Vicente ,&nbsp;Eva Rúmiz ,&nbsp;Rosa María Cardenal Piris ,&nbsp;Irene Elizondo Rua ,&nbsp;Jean Paul Vílchez ,&nbsp;Joan Antoni Gómez-Hospital","doi":"10.1016/j.recesp.2025.05.010","DOIUrl":"10.1016/j.recesp.2025.05.010","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The reliability of quantitative flow ratio (QFR) has been questioned. Our aim was to evaluate the diagnostic accuracy of QFR in intermediate nonculprit lesions during the index ST-segment elevation myocardial infarction (STEMI) procedure compared with positive pressure wire-based fractional flow reserve (FFR ≤<!--> <!-->0.80) in a staged procedure.</div></div><div><h3>Methods</h3><div>This was a substudy of the multicenter, controlled, and randomized VULNERABLE trial, including 428 intermediate nonculprit lesions from 388 consecutive STEMI patients undergoing FFR assessment in a staged procedure between 1 and 60 days. Off-line QFR analyses were performed during both the index and staged procedures. The primary objective was to assess the diagnostic accuracy of index QFR compared with staged positive FFR.</div></div><div><h3>Results</h3><div>Angiographic vessel diameter (2.80<!--> <!-->±<!--> <!-->0.59 vs 2.91<!--> <!-->±<!--> <!-->0.57<!--> <!-->mm; <em>P</em> <!-->&lt;<!--> <!-->.01), stenosis severity (51.33<!--> <!-->±<!--> <!-->8.04% vs 50.54<!--> <!-->±<!--> <!-->7.63%; <em>P</em> <!-->=<!--> <!-->.053), and QFR values (0.85<!--> <!-->±<!--> <!-->0.09 vs 0.86<!--> <!-->±<!--> <!-->0.09; <em>P</em> <!-->=<!--> <!-->.120) showed minimal changes between the index and staged procedures. Moderate concordance was observed between index QFR and staged FFR (kappa index<!--> <!-->=<!--> <!-->0.629; intraclass correlation coefficient<!--> <!-->=<!--> <!-->0.641). The diagnostic accuracy of index QFR for predicting positive FFR was good (area under the curve<!--> <!-->=<!--> <!-->0.825). An index QFR cutoff ≤<!--> <!-->0.80 showed moderate sensitivity (72%) and excellent specificity (91%). An index QFR ≤<!--> <!-->0.87 achieved a sensitivity of 86% for detecting lesions with positive FFR, with 55% of lesions presenting QFR ≤<!--> <!-->0.87 at the index procedure.</div></div><div><h3>Conclusions</h3><div>Index QFR demonstrated good diagnostic accuracy for identifying lesions with positive FFR in a staged procedure. However, an index QFR cutoff value of ≤<!--> <!-->0.80 showed moderate sensitivity and may underdiagnose approximately 3 out of 10 lesions with positive FFR. An index QFR ≤<!--> <!-->0.87 provided higher sensitivity and may help avoid invasive (staged) procedures in many patients.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 49-58"},"PeriodicalIF":5.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Registro español de hemodinámica y cardiología intervencionista. XXXIV informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2024) 血液动力学和介入心脏病学的西班牙注册。西班牙心脏病学会介入心脏病学会第三十四次正式报告(1990-2024年)
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-10 DOI: 10.1016/j.recesp.2025.07.003
Teresa Bastante , Dabit Arzamendi , Javier Martín-Moreiras , Ana Belén Cid-Álvarez , en representación de la ACI-SEC

Introduction and objectives

This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).

Methods

All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.

Results

A total of 118 hospitals participated, with a marked increase in the number of catheterization laboratories. The number of diagnostic procedures rose by 3.6%. Percutaneous coronary interventions (PCI) also increased. Although PCI volumes grew compared with 2023, the trend toward a reduction in the number of stents used was confirmed, with greater use of drug-coated balloons both as standalone treatment and in hybrid strategies (14.3% of PCIs involved drug-coated balloons). Overall, the use of intracoronary diagnostic techniques increased, with 10.6% of PCIs guided by intracoronary imaging. Plaque modification techniques also continued to grow. Primary PCI increased slightly and remained the predominant treatment for myocardial infarction (98%). Structural interventions continued to expand, with substantial growth in transcatheter aortic valve implantation, percutaneous edge-to-edge mitral repair, tricuspid interventions, and left atrial appendage closure. Interventional treatment for acute pulmonary embolism increased again in 2024, especially with dedicated devices.

Conclusions

The 2024 Spanish cardiac catheterization and interventional cardiology registry showed overall growth in all procedures, both coronary and structural.
本报告介绍了西班牙心脏病学会介入心脏病学会(ACI-SEC) 2024年的活动数据。方法邀请西班牙所有介入心脏病实验室完成在线调查。数据分析由外部公司进行,然后由ACI-SEC董事会进行审查和提交。结果共有118家医院参与,导尿实验室数量明显增加。诊断程序的数量增加了3.6%。经皮冠状动脉介入治疗(PCI)也有所增加。尽管PCI容量与2023年相比有所增加,但支架使用数量减少的趋势得到证实,药物包被球囊作为独立治疗和混合策略的使用更多(14.3%的PCI涉及药物包被球囊)。总体而言,冠状动脉内诊断技术的使用增加,10.6%的pci由冠状动脉内成像引导。斑块修饰技术也在继续发展。首次PCI治疗略有增加,仍然是心肌梗死的主要治疗方法(98%)。结构性干预继续扩大,经导管主动脉瓣置入术、经皮二尖瓣边缘修复术、三尖瓣介入术和左心房附件闭合术的数量大幅增加。2024年,急性肺栓塞的介入治疗再次增加,特别是使用专用设备。2024年西班牙心导管和介入心脏病学登记显示,所有手术,包括冠状动脉和结构手术,都有所增长。
{"title":"Registro español de hemodinámica y cardiología intervencionista. XXXIV informe oficial de la Asociación de Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2024)","authors":"Teresa Bastante ,&nbsp;Dabit Arzamendi ,&nbsp;Javier Martín-Moreiras ,&nbsp;Ana Belén Cid-Álvarez ,&nbsp;en representación de la ACI-SEC","doi":"10.1016/j.recesp.2025.07.003","DOIUrl":"10.1016/j.recesp.2025.07.003","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).</div></div><div><h3>Methods</h3><div>All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board<em>.</em></div></div><div><h3>Results</h3><div>A total of 118 hospitals participated, with a marked increase in the number of catheterization laboratories. The number of diagnostic procedures rose by 3.6%. Percutaneous coronary interventions (PCI) also increased. Although PCI volumes grew compared with 2023, the trend toward a reduction in the number of stents used was confirmed, with greater use of drug-coated balloons both as standalone treatment and in hybrid strategies (14.3% of PCIs involved drug-coated balloons). Overall, the use of intracoronary diagnostic techniques increased, with 10.6% of PCIs guided by intracoronary imaging. Plaque modification techniques also continued to grow. Primary PCI increased slightly and remained the predominant treatment for myocardial infarction (98%). Structural interventions continued to expand, with substantial growth in transcatheter aortic valve implantation, percutaneous edge-to-edge mitral repair, tricuspid interventions, and left atrial appendage closure. Interventional treatment for acute pulmonary embolism increased again in 2024, especially with dedicated devices.</div></div><div><h3>Conclusions</h3><div>The 2024 Spanish cardiac catheterization and interventional cardiology registry showed overall growth in all procedures, both coronary and structural.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 11","pages":"Pages 992-1003"},"PeriodicalIF":5.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inteligencia artificial (IA): una de arena… 人工智能(AI):一个沙…
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-05 DOI: 10.1016/j.recesp.2025.07.001
Fernando A. Navarro
{"title":"Inteligencia artificial (IA): una de arena…","authors":"Fernando A. Navarro","doi":"10.1016/j.recesp.2025.07.001","DOIUrl":"10.1016/j.recesp.2025.07.001","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 1-2"},"PeriodicalIF":5.9,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
El diagnóstico etiológico en miocarditis: ¿una asignatura aún pendiente? 心肌炎的病因诊断:一个有待研究的课题?
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-04 DOI: 10.1016/j.recesp.2025.06.011
Fernando Domínguez
{"title":"El diagnóstico etiológico en miocarditis: ¿una asignatura aún pendiente?","authors":"Fernando Domínguez","doi":"10.1016/j.recesp.2025.06.011","DOIUrl":"10.1016/j.recesp.2025.06.011","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 12","pages":"Pages 1118-1119"},"PeriodicalIF":5.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145579137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aumento de la mortalidad cardiovascular en personas con discapacidad. Un nuevo reto que hay que afrontar 残疾人心血管死亡率上升。新挑战
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-03 DOI: 10.1016/j.recesp.2025.05.014
Pedro Armario , Montserrat Martín-Baranera
{"title":"Aumento de la mortalidad cardiovascular en personas con discapacidad. Un nuevo reto que hay que afrontar","authors":"Pedro Armario ,&nbsp;Montserrat Martín-Baranera","doi":"10.1016/j.recesp.2025.05.014","DOIUrl":"10.1016/j.recesp.2025.05.014","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 1","pages":"Pages 13-14"},"PeriodicalIF":5.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estrategia de reducción de stents frente a revascularización coronaria percutánea convencional en el IAMCEST: diseño del ensayo COPERNICAN IAMCEST中支架减少与常规经皮冠状动脉再充血的战略:COPERNICAN试验设计
IF 5.9 2区 医学 Q2 Medicine Pub Date : 2025-07-03 DOI: 10.1016/j.recesp.2025.05.006
Jorge Sanz-Sánchez , Sandra Santos Martínez , Eva Rumiz González , Juan Francisco Oteo Domínguez , David Tejada Ponce , Antonio Gómez Menchero , Guillermo Sánchez Elvira , Georgina Fuertes Ferre , Fernando Rivero Crespo , Antonela Lukic Otanovic , José Díaz Fernández , Eladio Galindo Fernández , Cristóbal Urbano Carrillo , Neus Salvatella Giralt , Mauricio Torres Sánchez , Arturo García Touchard , Borja Ibáñez Cabeza , Giulio Stefanini , Fernando Alfonso Manterola , Héctor García García , Ignacio J. Amat-Santos

Introduction and objectives

Primary percutaneous coronary intervention (PCI) with drug-eluting stent implantation (DES) is the standard of treatment in patients presenting with ST-segment elevation myocardial infarction (STEMI). However, target lesion failure can occur due to stent underexpansion, malapposition, hypersensitivity, fracture, and neoatherosclerosis. Drug-coated balloons (DCB) represent a potential alternative supported by the concept of “leaving nothing behind.” The aim is to compare a reduced stent strategy based on DCB- with DES-PCI in patients presenting with STEMI.

Methods

Prospective, pragmatic, multicenter, noninferiority, randomized clinical trial.

Results

A total of 1 272 patients presenting with STEMI will be randomized to any paclitaxel-DCB vs any sirolimus-DES (both with CE approval) for all culprit and nonculprit lesions during PCI. The primary endpoint will be target-lesion failure: cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization at 12-month follow-up. An independent clinical events committee masked to treatment allocation will adjudicate all suspected events. Clinical follow-up will be performed after 1 month (30 days ± 5 days) and 1 year (365 days ± 30 days). An extended follow-up at 3, 5, and 10 years is planned.

Conclusions

The COPERNICAN trial will be the first randomized study comparing clinical outcomes of DCB vs DES in STEMI patients.
ClinicalTrials.gov: NCT06353594.
简介和目的经皮冠状动脉介入治疗(PCI)联合药物洗脱支架植入术(DES)是st段抬高型心肌梗死(STEMI)患者的标准治疗方法。然而,由于支架扩张不足、错位、过敏、骨折和新动脉粥样硬化,靶病变失败可能发生。药物涂层气球(DCB)代表了一种潜在的替代方案,它得到了“不留下任何东西”概念的支持。目的是比较基于DCB-和DES-PCI的缩小支架策略在STEMI患者中的应用。方法前瞻性、实效性、多中心、非劣效性、随机临床试验。结果共有1 272例STEMI患者将被随机分配到任何紫杉醇- dcb和任何西罗莫司- des(均获得CE批准),用于PCI期间所有罪魁祸首和非罪魁祸首病变。在12个月的随访中,主要终点将是靶病变衰竭:心源性死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建术。一个独立的临床事件委员会负责治疗分配,对所有可疑事件进行裁决。临床随访时间分别为1个月(30天±5天)和1年(365天±30天)。计划延长随访3年、5年和10年。COPERNICAN试验将是首个比较DCB和DES治疗STEMI患者临床结果的随机研究。
{"title":"Estrategia de reducción de stents frente a revascularización coronaria percutánea convencional en el IAMCEST: diseño del ensayo COPERNICAN","authors":"Jorge Sanz-Sánchez ,&nbsp;Sandra Santos Martínez ,&nbsp;Eva Rumiz González ,&nbsp;Juan Francisco Oteo Domínguez ,&nbsp;David Tejada Ponce ,&nbsp;Antonio Gómez Menchero ,&nbsp;Guillermo Sánchez Elvira ,&nbsp;Georgina Fuertes Ferre ,&nbsp;Fernando Rivero Crespo ,&nbsp;Antonela Lukic Otanovic ,&nbsp;José Díaz Fernández ,&nbsp;Eladio Galindo Fernández ,&nbsp;Cristóbal Urbano Carrillo ,&nbsp;Neus Salvatella Giralt ,&nbsp;Mauricio Torres Sánchez ,&nbsp;Arturo García Touchard ,&nbsp;Borja Ibáñez Cabeza ,&nbsp;Giulio Stefanini ,&nbsp;Fernando Alfonso Manterola ,&nbsp;Héctor García García ,&nbsp;Ignacio J. Amat-Santos","doi":"10.1016/j.recesp.2025.05.006","DOIUrl":"10.1016/j.recesp.2025.05.006","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Primary percutaneous coronary intervention (PCI) with drug-eluting stent implantation (DES) is the standard of treatment in patients presenting with ST-segment elevation myocardial infarction (STEMI). However, target lesion failure can occur due to stent underexpansion, malapposition, hypersensitivity, fracture, and neoatherosclerosis. Drug-coated balloons (DCB) represent a potential alternative supported by the concept of “leaving nothing behind.” The aim is to compare a reduced stent strategy based on DCB- with DES-PCI in patients presenting with STEMI.</div></div><div><h3>Methods</h3><div>Prospective, pragmatic, multicenter, noninferiority, randomized clinical trial.</div></div><div><h3>Results</h3><div>A total of 1 272 patients presenting with STEMI will be randomized to any paclitaxel-DCB vs any sirolimus-DES (both with CE approval) for all culprit and nonculprit lesions during PCI. The primary endpoint will be target-lesion failure: cardiac death, target-vessel myocardial infarction, or ischemia-driven target lesion revascularization at 12-month follow-up. An independent clinical events committee masked to treatment allocation will adjudicate all suspected events. Clinical follow-up will be performed after 1 month (30 days<!--> <!-->±<!--> <!-->5 days) and 1 year (365 days<!--> <!-->±<!--> <!-->30 days). An extended follow-up at 3, 5, and 10 years is planned.</div></div><div><h3>Conclusions</h3><div>The COPERNICAN trial will be the first randomized study comparing clinical outcomes of DCB vs DES in STEMI patients.</div><div>ClinicalTrials.gov: <span><span>NCT06353594</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"79 2","pages":"Pages 100-105"},"PeriodicalIF":5.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146039956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista espanola de cardiologia
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1